Semaglutide 14mg has also been associated with cardiovascular benefits. The SUSTAIN-6 trial demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients treated with Semaglutide, highlighting its potential to improve overall cardiovascular health in diabetic patients.
How Semaglutide 14mg is Revolutionizing Diabetes Treatment